Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 in Patients with Moderate to Severe Asthma
NCT06642961Phase 2Recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Jul 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of telikibart in asthma, sponsored by Zhixiang Jintai. Started Jul 2022; status: recruiting.
02
Drugs
telikibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06642961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642961.